Skip to content
Search

Latest Stories

Study shows scale of prevalence of a condition that can cause type 2 diabetes and high blood pressure

A study by scientists in a UK university has shown the scale of the prevalence of a condition that can lead to various cardiometabolic diseases.

The study published in the Annals of Internal Medicine journal on Tuesday (January 4) has prompted calls for changes to healthcare policy after researchers revealed, for the first time, the scale of the impact of the condition associated with benign tumors that can lead to type 2 diabetes and high blood pressure.


Up to 10 per cent of adults have a benign tumour, or lump, known as an 'adrenal incidentaloma' in their adrenal glands which can be associated with the overproduction of hormones including the stress steroid hormone cortisol that can lead to type 2 diabetes and high blood pressure.

Previous small studies suggested that one in three adrenal incidentalomas produce excess cortisol, a condition called mild autonomous cortisol secretion (MACS).

An international research team led by the University of Birmingham carried out the largest ever prospective study of over 1,305 patients with adrenal incidentalomas to assess their risk of high blood pressure and type 2 diabetes and their cortisol production by comparing patients with and without MACS.

The study was also the first to undertake a detailed analysis of the steroid hormone production in patients by analysing cortisol and related hormones by mass spectrometry in the 24-hour urine samples they collected.

Their study findings showed that MACS is much more prevalent than previously reported: with almost every second patient in the study with an adrenal incidentaloma having MACS.

Notably, 70 per cent of patients with MACS were women and most of them were of postmenopausal age (aged over 50). Following their findings, the researchers estimated that up to 1.3 million adults in the UK could have MACS.

Considering that around two out of three of these patients are women, MACS is potentially a key contributor to women's metabolic health, in particular in women after menopause.

The first author Dr Alessandro Prete, of the University of Birmingham's Institute of Metabolism and Systems Research, said: "Compared to those without MACS, we observed that patients with MACS were more likely to be diagnosed with high blood pressure and to require three or more tablets to achieve an adequate blood pressure control.

When we looked at patients with a diagnosis of type 2 diabetes, those with MACS were twice more likely to be treated with insulin, indicating that other medications haven't helped manage their blood sugar levels.

In conclusion, our study found that MACS is very frequent and is an important risk condition for high blood pressure and type 2 diabetes, especially in older women, and the impact of MACS on high blood pressure and type 2 diabetes risk has been underestimated until now."

Senior author Professor Wiebke Arlt, director of the University of Birmingham's Institute of Metabolism and Systems Research, said: "Previous studies suggested that MACS is associated with poor health. However, our study is the largest ever study to establish conclusively the extent of the risk and severity of high blood pressure and type 2 diabetes in patients with MACS.

"Our hope is that this research will put a spotlight on this condition and increase awareness of its impact on health. We advocate that all patients who are found to carry an adrenal incidentaloma are tested for MACS and have their blood pressure and glucose levels measured regularly."

The study was funded by Diabetes UK, the European Commission, the Medical Research Council, and the Claire Khan Trust Fund at University Hospitals Birmingham Charity.

More For You

Omega Pharmacy in Derbyshire Finds New Owner in Just 18 Days

Omega Pharmacy

Christie & Co

Omega Pharmacy in Derbyshire sold in just 18 days

Omega Pharmacy in Derbyshire has found a new owner in less than three weeks after being put on the market.

The pharmacy was previously owned by husband-and-wife duo Manny and Poonam Rai, who decided to sell it after a short period of ownership to focus on their other pharmacy in Coventry, according to Christie & Co.

Keep ReadingShow less
DHSC announces second list of March 2025 price concessions

A price concession only applies for the month it is granted.

Getty Images

March price concessions list released; prescription charge remains unchanged

The Department of Health and Social Care (DHSC) has released a second list of price concessions for March 2025, following ongoing discussions with Community Pharmacy England (CPE) regarding medicine pricing concerns raised by pharmacy owners.

A price concession is introduced when pharmacy contractors are unable to source a drug at or below the reimbursement price set out in the Drug Tariff.

Keep ReadingShow less
AstraZeneca partners with CEPI to develop multi-specific influenza antibody

AstraZeneca-CEPI collaboration aims to increase global access to antibody-based interventions

Getty Images

AstraZeneca secures £33M CEPI funding to develop multi-specific influenza antibody

AstraZeneca has joined forces with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance an innovative antibody technology that could help tackle future infectious disease outbreaks and pandemics swiftly and more affordably.

CEPI will provide up to US$43.5 million (£33.6 million) in funding to support the biopharmaceutical company in evaluating a type of antibody, known as a VHH (Variable Heavy domain of a Heavy chain -only antibody), through preclinical proof-of-concept studies and Phase 1 clinical trials.

Keep ReadingShow less
Community Pharmacy Patient Safety Group announces new vice-chair

Martin Sadr-Kazemi 's appointment follows the passing of Dr. José Moss in January 2025.

Martin Sadr-Kazemi appointed vice-chair of Community Pharmacy Patient Safety Group

The Community Pharmacy Patient Safety Group (CPPSG) has announced the appointment of Martin Sadr-Kazemi as its new vice-chair.

Martin, currently the medication safety officer and deputy superintendent pharmacist at Rowlands Pharmacy, has been an integral member of the CPPSG since its formation a decade ago, actively contributing to various initiatives.

Keep ReadingShow less
"My work benefits all across London," says ambulance pharmacy technician

Mahrukh Jaffar

Pic credit: London Ambulance Service

"My work benefits all across London," says ambulance pharmacy technician

Mahrukh Jaffar will create history when she becomes the first apprentice to become a qualified pharmacy technician through the London Ambulance Service.

Jaffar is just days away from completing her registration with the General Pharmaceutical Council.

Keep ReadingShow less